Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA OFFICE OF EPIDEMIOLOGY DIRECTOR FAICH MOVING TO BESSELAAR-PACT

Executive Summary

FDA OFFICE OF EPIDEMIOLOGY DIRECTOR FAICH MOVING TO BESSELAAR-PACT as a VP in August. The 47 year-old Faich, MD, who will retire from the agency after 20 years in the Public Health Service, has served as director of the Office of Epidemiology and Biostatistics for six years, where he has coordinated adverse reaction reporting and post-marketing surveillance. FDA has not named a replacement for the position. The agency reportedly has not yet decided whether it will conduct an internal or external search for his successor. Next in line to Faich is the office's deputy director Charles Anello, who has been with agency for 20 years. Prior to coming to FDA, Faich spent two years in the Surgeon General's Office. Before that he performed epidemiological research for the Centers for Disease Control for 12 years. At Besselaar, Faich will be responsible for Phase IV studies and drug safety reviews. Corning Laboratory Science Division subsidiary Besselaar, founded by former Merck exec G.H. Besselaar, acquired PACT (Philadelphia Association for Clinical Trials) in December ("The Pink Sheet" Jan. 1, T&G-10). The new corporation says it conducts Phase I-IV studies for at least half of the top 50 U.S. pharmaceutical manufacturers. The company also maintains offices in Europe, Japan and Australia.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS017374

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel